Legal & General Group Plc grew its position in shares of Intersect ENT, Inc. (NASDAQ:XENT) by 3.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,939 shares of the medical equipment provider’s stock after buying an additional 255 shares during the quarter. Legal & General Group Plc’s holdings in Intersect ENT were worth $193,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in XENT. Cornerstone Capital Management Holdings LLC. increased its holdings in shares of Intersect ENT by 109.1% in the 1st quarter. Cornerstone Capital Management Holdings LLC. now owns 11,500 shares of the medical equipment provider’s stock valued at $196,000 after purchasing an additional 6,000 shares in the last quarter. American International Group Inc. increased its holdings in shares of Intersect ENT by 7.1% in the 1st quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock valued at $269,000 after purchasing an additional 1,037 shares in the last quarter. Personal Capital Advisors Corp purchased a new position in shares of Intersect ENT in the 2nd quarter valued at about $273,000. State of Wisconsin Investment Board purchased a new position in shares of Intersect ENT in the 2nd quarter valued at about $531,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of Intersect ENT in the 1st quarter valued at about $590,000. Institutional investors own 83.12% of the company’s stock.
In other Intersect ENT news, insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $29.03, for a total transaction of $580,600.00. Following the sale, the insider now owns 580,868 shares in the company, valued at approximately $16,862,598.04. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Richard E. Kaufman sold 22,425 shares of the business’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $30.22, for a total value of $677,683.50. Following the sale, the chief operating officer now owns 149,821 shares in the company, valued at approximately $4,527,590.62. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 147,063 shares of company stock worth $4,381,229. Corporate insiders own 13.70% of the company’s stock.
XENT has been the subject of a number of research analyst reports. BidaskClub downgraded shares of Intersect ENT from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Canaccord Genuity reiterated a “buy” rating and issued a $32.00 price target on shares of Intersect ENT in a report on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 price target on shares of Intersect ENT and gave the company a “buy” rating in a report on Wednesday, August 2nd. Zacks Investment Research upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Thursday, October 5th. Finally, Bank of America Corporation increased their price target on shares of Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a report on Monday, September 11th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $27.70.
Intersect ENT, Inc. (XENT) opened at 27.85 on Friday. The firm’s 50-day moving average is $30.23 and its 200 day moving average is $26.04. The stock’s market capitalization is $812.91 million. Intersect ENT, Inc. has a 12-month low of $7.65 and a 12-month high of $33.25.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.11. The firm had revenue of $24.00 million for the quarter, compared to the consensus estimate of $22.62 million. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The business’s revenue for the quarter was up 24.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.21) EPS. Equities research analysts anticipate that Intersect ENT, Inc. will post ($0.61) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This report was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2017/10/13/legal-general-group-plc-has-193000-holdings-in-intersect-ent-inc-xent.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.